Live Breaking News & Updates on Hans Kolam

Stay updated with breaking news from Hans kolam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Correction: Active Biotech Year End Report 2021

The correction refers to the administrative costs for the period January - December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15 ....

Hans Kolam , Erik Vahtola , Loncode Institute , Annual Report , Active Biotech , Chief Medical Officer , End Report ,

Investegate |Active Biotech Announcements | Active Biotech: Correction: Active Biotech Year End Report 2021

Investegate announcements from Active Biotech, Correction: Active Biotech Year End Report 2021 ....

Hans Kolam , Erik Vahtola , Loncode Institute , Active Biotech Year End Report , Annual Report , Active Biotech , Chief Medical Officer , Investegate Announcements , Investegate Company Announcements , Active Biotech , Lobenewswire And Globenewswire ,

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Erasmus Universiteit Medisch Centrum , Active Biotech , Cell Stem , Globe Newswire ,

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Erasmus Universiteit Medisch Centrum , Active Biotech , Cell Stem ,

Investegate |Active Biotech Announcements | Active Biotech: Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Investegate announcements from Active Biotech, Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis ....

Hans Kolam , Rebekka Schneider , Rebekka Schneiders , Erasmus Universiteit Medisch , Loncode Institute , Active Biotech , Erasmus Universiteit Medisch Centrum , Cell Stem , Investegate Announcements , Investegate Company Announcements , Active Biotech , Lobenewswire And Globenewswire ,